On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define acceptable tests and increase qualifying result cutoffs to be used for manufacturing COVID-19 convalescent plasma with high titers of anti-SARS-CoV-2 antibodies.
We are currently evaluating our options to determine if we can provide additional testing services using one of the newly defined assays. Please reach out to your customer service manager if your organization is considering CCP testing under the updated guidelines.
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
National Blood Donor Month has been observed in January since 1970, with the goal of increasing bloo...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...